Emerald Advisers, LLC Gossamer Bio, Inc. Transaction History

Emerald Advisers, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 25, 2022	SELL	$7.21 - $14.88 $8.96 Million - $18.5 Million	-1,242,252 Reduced 66.69%	620,370 $7.43 Million
Q2 2022 Jul 29, 2022	SELL	$5.97 - $9.97 $519,121 - $866,941	-86,955 Reduced 4.46%	1,862,622 $15.6 Million
Q1 2022 Apr 29, 2022	BUY	$8.44 - $12.49 $1.51 Million - $2.23 Million	178,658 Added 10.09%	1,949,577 $16.9 Million
Q4 2021 Feb 02, 2022	BUY	$10.12 - $14.07 $2.58 Million - $3.59 Million	254,916 Added 16.82%	1,770,919 $20 Million
Q3 2021 Oct 28, 2021	BUY	$7.25 - $13.23 $1.73 Million - $3.16 Million	239,007 Added 18.72%	1,516,003 $19.1 Million
Q2 2021 Jul 29, 2021	BUY	$8.0 - $9.75 $6.6 Million - $8.05 Million	825,566 Added 182.88%	1,276,996 $10.4 Million
Q1 2021 Apr 29, 2021	BUY	$8.63 - $10.94 $3.9 Million - $4.94 Million	451,430 New	451,430 $4.18 Million

109

167M

430K

519K

Ticker GOSS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,954,000
Market Cap $84.6M
Description
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...

Get notified when there are updates to the investment portfolio of Emerald Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on Emerald Advisers, LLC with notifications on news.